Beam Therapeutics' Q3 Results Attract Clear Street, Raises PT to $37

RBC Capital raised Ocular Therapeutix's (OCUL) price target to $24 from $17, citing strong execution in its SOL-1 wet age-related macular degeneration study. The company's patient retention and adherence have exceeded 95%, and it has excess cash reserves of approximately $790 million. Ocular Therapeutix has a solid growth trajectory and potentially significant market share gains in both wAMD and DR segments.